Answers are grounded in this paper and cite their sources.
BACKGROUND & AIMS: The incidence of gastric cardia adenocarcinoma has increased with the increasing prevalence of metabolic syndrome. Peroxisome proliferator-activated receptor-δ emerged as a key target in metabolic syndrome and carcinogenesis. We aimed to elucidate its role in gastric cardia adenocarcinoma progression. METHODS: Male keratin 19 promoter-Wnt1/cyclooxygenase-2 and microsomal prostaglandin E synthase-1 overexpressing mice were fed a control or high-fat diet with or without the peroxisome proliferator-activated receptor-δ agonist GW-501516 or the peroxisome proliferator-activated receptor-δ antagonist GSK-3787. The involvement of Nrf2 in the peroxisome proliferator-activated receptor-δ-regulated, metabolism-driven tumorigenesis was examined by comparing wild-type and nuclear factor erythroid 2-related factor 2-deficient conditions. RESULTS: In high-fat diet + GSK-3787-treated keratin 19 promoter-Wnt1/cyclooxygenase-2 and microsomal prostaglandin E synthase-1 overexpressing mice with metabolic endotoxemia, granular-nodular tumors at the squamocolumnar junction were greater than those in the other groups. Intratumor expression of the NAD(P)H quinone dehydrogenase 1 and glutathione peroxidase 4 proteins increased and the plasma levels of dysbiosis-related metabolites for tumor energy metabolism increased. In high-fat diet + GSK-3787-treated nuclear factor erythroid 2-related factor 2-deficient mice, tumors shrank with decreases in NAD(P)H quinone dehydrogenase 1 and glutathione peroxidase 4 protein expression and increases in the malondialdehyde level and oxidized glutathione/reduced glutathione ratio, and the plasma levels of metabolites for energy metabolism and ferroptosis resistance decreased. The suppression of peroxisome proliferator-activated receptor-δ signaling in AGS cells treated with GSK-3787 or a small interfering RNA inhibited ferroptosis by increasing solute carrier family 7 member 11 expression and activating nuclear factor erythroid 2-related factor 2 signaling. Transfection with Nuclear Factor Erythroid 2-Related Factor 2 small interfering RNA decreased the GSK-3787-induced upregulation of solute carrier family 7 member 11, and Nuclear Factor Erythroid 2-Related Factor 2 directly regulates SLC7A11 transcription by binding to its promoter. CONCLUSIONS: Cotreatment with a high-fat diet and GSK-3787 may promote squamocolumnar junction tumor progression by suppressing ferroptosis through intratumoral nuclear factor erythroid 2-related factor 2 signaling and dysbiosis-related metabolites, indicating a negative role of peroxisome proliferator-activated receptor-δ signaling on metabolic syndrome-related squamocolumnar junction tumorigenesis.
No takes yet. Share an insight, caveat, or question.
Tanabe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: